Thiogenesis Therapeutics Company Description

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs.

Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome.

The company is headquartered in Toronto, Canada.

Thiogenesis Therapeutics, Corp.

Country	Canada
Industry	Biotechnology
Sector	Healthcare
CEO	Patrice Rioux

Contact Details

Address: 4 King Street West Toronto, Ontario M5H 1B6 Canada
Phone	888-223-9165
Website	thiogenesis.com

Stock Details

Ticker Symbol	TTI
Exchange	TSX Venture Exchange
Fiscal Year	January - December
Reporting Currency	CAD
SIC Code	2836

Key Executives

Name	Position
Dr. Patrice P. Rioux M.D., Ph.D.	Co-Founder, Chief Executive Officer and Director
Brook G. Riggins C.F.A.	Chief Financial Officer, Secretary and Director
Mary Jo Bagger	Consultant for Clinical Operations